Dr. Wayne Danter is the founder of 123Genetix and is a pioneer in the evolving interface between artificial intelligence (“AI”) and pharmacotherapeutics. He has conducted extensive research on the medical application of AI technologies to disease diagnosis, outcome prediction and personalized therapies. Much of his research has focused on developing Hybrid AI models of the relationships between molecular structure and biological activity. His research has been published in peer-reviewed journals and he has been an invited presenter and panelist at numerous international meetings.
Prior to founding 123Genetix, Dr. Danter was the President, CEO and CSO of Critical Outcome Technologies Inc., which he also founded. While at Critical Outcome Technologies, he invented a proprietary, AI-based technology platform that utilizes a series of predictive computer models to identify compounds with a high probability of being successfully developed from disease specific drug discovery and chemical optimization through preclinical testing and early clinical testing.
Earlier in his career, Dr. Danter was an Associate Professor of Medicine at the University of Western Ontario (now Western University). His clinical focus at the University was in General Cardiology, Cardiovascular Diseases associated with HIV, and Cardiovascular Risk Management. Dr. Danter trained at the University of Western Ontario in Internal Medicine, Clinical Pharmacology and Critical Care.
At 123Genetix, we believe that AI/machine learning has the potential to play a major role in the world of rare disease research by empowering researchers to: (1) develop new disease hypotheses; (2) design and run experimental simulations to test those hypotheses; (3) write better grants and (4) identify potential disease specific biomarkers.
About our blog
We intend to use this space to help you get to know 123Genetix, our team and our mission, as well as to create more awareness for rare diseases and the limitations their researchers face.